Letter to Shareholders by Geert Kersten!!
The shareholder letter posted by Geert Kersten last Friday is promising and here are some of the most relevant parts of it:
"We filed that very important additional clinical trial data with www.clinicaltrials.gov, the U.S. Government website for clinical trials, on March 22, 2022 and hoped that it would be public by now so that we could add the results to this letter. The information, however, is not yet public and could therefore not be included in this letter, but we hope that you will have seen the data by the time you receive this letter. Yet additional data will be presented and published in peer reviewed scientific forums in the future."
"I believe that we are well positioned to recover from this storm as well since 1) we have cash until about the end of 2023 and 2) we have a finished 10-year clinical trial that has shown large survival benefit in a large cancer population that represents an unmet medical need. We have hired leading experts in the field to help get Multikine approved for sale. We are also working on scientific publications and the validation of our full scale manufacturing facility dedicated to making Multikine."
"This is not a process where we can easily give simple and regular updates, as we must respect the integrity and confidentiality of the regulatory review process. Please keep in mind that we have dedicated our lives to this important project and we will do everything possible to make this happen."
And here some facts about Cel-Sci's current PPS and ownership:
45.6% institutional ownership
60.82% daily short volume on Friday but the PPS went up 4.0%!!
7.4 million shares (19.9% of the float) currently shorted
The total amount of shorted shares has increased by 0.3 million to 7.4 million shares. Any day from now we might get some news and the manipulation by the shorts (60.82% daily short volume on Friday) will finally come to an end! GLTAL! Tick tock, tick tock ...
